MetaCap

Replimune Group Quarterly Balance Sheet

NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

19.07-0.16 (-0.83%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Replimune Group financial position

As of Sep 30, 2026, Replimune Group reported total assets of $373.9 million, down 4.0% from a year earlier against total liabilities of $169.2 million. Shareholders' equity stood at $204.8 million, or 54.8% of assets. The company held $307.8 million in cash and equivalents against $99.8 million of debt, a net cash position of $208.1 million.

The current ratio (current assets divided by current liabilities) was 7.11, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.49.

Summary generated from market data by MetaCap's automated system. Methodology

Replimune Group balance sheet (quarterly)

Replimune Group quarterly balance sheet
Quarter (USD)Q2 20272026-09-30Q1 20272026-06-30Q4 20262026-03-31Q3 20262025-12-31Q2 20262025-09-30Q1 20262025-06-30Q4 20252025-03-31Q3 20252024-12-31Q2 20252024-09-30Q1 20252024-06-30Q4 20242024-03-31Q3 20242023-12-31
Cash & Equivalents307.83M185.36M209.02M122.95M102.30M97.37M111.12M172.25M113.49M151.66M74.46M97.67M
Short-Term Investments09.97M59.87M146.19M221.35M305.97M372.69M364.29M318.56M317.47M346.21M368.68M
Inventory9.87M—0—————————
Total Current Assets324.04M200.81M279.12M280.35M333.75M413.37M495.88M547.58M442.63M480.32M433.67M479.16M
Property, Plant & Equipment10.70M11.86M12.97M13.85M14.71M14.68M13.74M13.62M12.59M11.40M10.48M9.47M
Total Assets373.94M252.45M332.39M333.59M389.45M469.51M551.33M603.63M498.20M534.97M487.72M532.93M
Accounts Payable5.96M4.26M6.67M5.65M6.40M15.48M12.46M7.19M8.41M864.00K2.58M3.90M
Total Current Liabilities45.55M38.41M58.23M50.09M52.90M59.56M62.36M47.89M43.79M35.68M40.44M38.65M
Long-Term Debt99.77M84.11M83.31M47.63M47.21M46.79M46.38M45.96M45.57M45.19M44.81M44.43M
Total Liabilities169.16M146.80M166.23M123.05M126.11M132.79M135.49M121.25M116.74M108.51M113.21M111.39M
Shareholders' Equity204.78M105.64M166.16M210.54M263.34M336.71M415.84M482.37M381.46M426.45M374.51M421.54M
Retained Earnings-1.39B-1.33B-1.26B-1.19B-1.12B-1.04B-948.58M-874.45M-808.11M-755.05M-701.28M-646.21M
Total Debt99.77M84.11M83.31M47.63M47.21M46.79M46.38M45.96M45.57M45.19M44.81M44.43M
Net Cash (Debt)208.07M111.21M185.58M221.51M276.44M356.55M437.43M490.58M386.49M423.93M375.86M421.92M
Shares Outstanding94.81M83.98M82.72M79.63M78.40M77.81M77.09M77.01M68.39M68.31M61.42M61.39M

This table shows 12 quarterly periods of Replimune Group's balance sheet, from Q2 2027 back to Q3 2024, across 15 line items including cash & equivalents, short-term investments, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow REPL's reporting calendar. What is a balance sheet?

More financial data